Clinical Trials Logo
  1. Home
  2. Depression, Bipolar
  3. NCT03423680

A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression — APOLLO  

Depression, Bipolar Clinical Trial

Official title:
A Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel Group, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Treatment of Major Depressive Episode Associated With Bipolar I or II Disorder

Clinical Trial Summary

This is an 8-week, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of aripiprazole as an adjunctive treatment with mood stabilizer for the treatment of patients (outpatients or inpatients) with type I or II bipolar disorder accompanied by major depressive episode, without any psychotropic features. This study involves patients who are considered by the investigator not to have a proper improvement, despite receiving a mood stabilizer (lithium or valproic acid) for a sufficient (≥ 28 days) period of time during the current depressive episode.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03423680
Study type Interventional
Source Korea Otsuka Pharmaceutical Co., Ltd.
Contact Hoyoung Lee
Phone 82-2-3287-9238
Email hoyounglee@otsuka.co.kr
Status Recruiting
Phase Phase 3
Start date February 22, 2018
Completion date November 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Not yet recruiting NCT05958940 - BioClock: Bright Light Therapy for Depressive Disorders N/A
Recruiting NCT02919280 - Dallas 2K: A Natural History Study of Depression
Completed NCT00060489 - Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression Phase 3
Recruiting NCT05767073 - LIVES: Personalized Lifestyle Intervention for Patients With Depression N/A
Completed NCT04121091 - Pramipexole to Target "Anhedonic Depression" Phase 2
Recruiting NCT04057378 - Optimal Electrical Stimulus During Electroconvulsive Therapy Phase 4
Completed NCT03287037 - The Effects of tDCS on Depressive Symptoms,Neurocognitive Function and HRV in Unipolar Depression and Bipolar Depression N/A
Completed NCT00483548 - Adjunctive Ziprasidone in the Treatment of Bipolar I Depression Phase 3
Not yet recruiting NCT05568823 - Biomarkers of ANTidepressant RESponse and Development Risk of Bipolar Disorder N/A
Completed NCT00191399 - Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response Phase 4
Recruiting NCT05436613 - Transcranial Direct Current Stimulation Therapy for Bipolar Depression N/A
Completed NCT03538275 - Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
Recruiting NCT04846010 - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 Phase 1/Phase 2
Withdrawn NCT02625779 - Combined Cytidine and Creatine-containing Drug in the Treatment of the Bipolar Depression Phase 2
Not yet recruiting NCT06462196 - Natural History of Depression, Bipolar Disorder and Suicide Risk
Recruiting NCT02778256 - Study of the Effectiveness of Vestibular Stimulation Treatment in the Depressive Phase of Bipolar Disorder N/A
Active, not recruiting NCT04643210 - Management of my Bipolarity Intervention in Bipolar Disorder Patients N/A
Completed NCT01396447 - Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression Phase 2
Enrolling by invitation NCT02827045 - Study of a Vestibular Biomarker of Phase in Bipolar Disorder